



(51) International Patent Classification:

A61K 31/517 (2006.01) A61K 45/06 (2006.01)
A61K 31/4468 (2006.01) A61K 39/00 (2006.01)
A61K 31/445 (2006.01) A61K 35/00 (2006.01)

(21) International Application Number:

PCT/SG2023/050654

(22) International Filing Date:

29 September 2023 (29.09.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202260162T 22 November 2022 (22.11.2022) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: TAY, Rong En; c/o Singapore Immunology Network, 8A Biomedical Grove, Immunos, Singapore 138648 (SG). RENIA, Laurent; c/o Singapore Immunology Network, 8A Biomedical Grove, Immunos, Singapore 138648 (SG). RÖTZSCHKE, Olaf; c/o Singapore Im-

munology Network, 8A Biomedical Grove, Immunos, Singapore 138648 (SG). HO, Charmaine; 1 Dundee Road Queens Peak, #13-09, Singapore 149456 (SG).

(74) Agent: DONALDSON & BURKINSHAW LLP; P.O. Box 3667, Robinson Road Post Office, Singapore 905667 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

(54) Title: SEROTONIN RECEPTOR AS A TARGET FOR THERAPY




Fig. 3

(57) **Abstract:** There is provided a serotonin receptor 5-HT2A inhibitor or composition comprising serotonin receptor 5-HT2A inhibitor for use in treating a proliferative disease in a subject in need thereof. Also disclosed are use of serotonin receptor 5-HT2A inhibitor in the manufacture of a medicament for treating proliferative disease in a subject and methods of treatment thereof. Also disclosed are pharmaceutical composition or combination therapy comprising a serotonin receptor 5-HT2A inhibitor and an immune checkpoint blockade/ICB therapy.

[Continued on next page]

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))*